

Online resource 5

Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma

Authors:

Adriana Olar, Khalida M Wani, Charmaine D Wilson, Gelareh Zadeh, Franco DeMonte, David TW Jones, Stefan M Pfister, Erik P Sulman, Kenneth D Aldape

Corresponding author:

Adriana Olar, M.D.
Depts. of Pathology and Laboratory Medicine & Neurosurgery
Medical University of South Carolina & Hollings Cancer Center
Bioengineering Building, BE 404
68th President St,
Charleston, SC, 29425, USA
Tel: 843-876-2287
Fax: 843-876-2299
E-mail: adriana_olar@yahoo.com, olar@musc.edu

283-bMMC - Overall median RFS




Figure O.R.5.1

Kaplan-Meier survival analysis for all samples (both the training and validation datasets together, $n=137$) grouped by 283-bMMC. We noted that although the separation of the curves was highly statistically significant, the median RFS for the poor prognosis group is rather high at ~10 years (range: 0.10-17.61). We further optimized a predictor able to identify aggressive meningioma cases more accurately.

64-MMP - Overall median RFS




Figure O.R.5.2

Kaplan-Meier survival analysis for all samples (both the training and validation datasets together, n=137) grouped by 64-MMP. After optimizing the 64-MMP predictor the 64-MMP-UNFAV group had a lower median RFS of only 2.13 years (range: 0.31-12.07) supporting earlier recurrence detection.